Assessment of endothelial dysfunction in acute coronary syndromes;Endotheliale funktionsstorung bei patienten mit akutem koronarsyndrom

Herz

Volumn 24, Issue 7, 1999, Pages 534-543

  Fichtlscherer, Stephan ^a   Zeiher, Andreas M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute coronary syndromes; Assessment of endothelial function; Endothelial function; Endothelin; Oxidative stress

Indexed keywords

ENDOTHELIN;

CELL PROLIFERATION; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; PATIENT MONITORING; PLETHYSMOGRAPHY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; HEART INFARCTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PLATELET AGGREGATION;

EID: 0033216840     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044225     Document Type: Review

References (100)

1. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25:155-61.
2. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B-4B.
3. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
4. Basaran Y, Basaran MM, Babacan KF, et al. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 1993;44:332-7.
5. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting responses to drugs and mediators. Hypertension 1995;25:918-23.
6. Bertrand ME, Lablanche JM, Tilmant PY, et al. The provocation of coronary arterial spasm in patients with recent transmural myocardial infarction. Eur Heart J 1983;4:532-5.
7. Bertrand ME, Lablanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients under-going coronary arteriography. Circulation 1982;65:1299-306.
8. Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in humans. Circulation 1996;94:490-7.
9. Bhagat K, Moss R, Collier J, et al. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996;32:822-9.
10. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042-7.
11. Bogaty P, Hackett D, Davies G, et al. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994;90:5-11.
12. Britten MB, Zeiher AM, Schächinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999;245:315-27.
13. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
14. Celermajer D, Sorenson K, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
15. Chowienczyk P, Watts G, Cockcroft J, et al. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholeserolaemia. Lancet 1992;340:1430-2.
16. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-49.
17. Creager M, Gallagher S, Girerd X, et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
18. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation 1997;95:2293-7.
19. Diaz MN, Frei B, Vita JA, et al. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
20. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-5.
21. Diodati JG, Dakak N, Gilligan DM, et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998;98:17-24.
22. Elsner M. Methods for coronary functional assessment. Herz 1998;23:78-96.
23. Fichtlscherer S, Rosenberger G, Auch-Schwelk W, et al. Acute coronary syndromes are associated with impaired systemic vascular reactivity. Circulation 1999;98:Suppl I:698.abstract.
24. Freedman JE, Ting B, Hankin B, et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998;98:1481-6.
25. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-50.
26. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-8.
27. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-75.
28. Gage JE, Hess OM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-76.
29. Gates P, Marwood S, Jelinek M, et al. Unreported symptomatic and asymptomatic ischaemic heart disease in patients presenting with TIA or minor stroke detected by the London School of Hygiene Cardiovascular Questionnaire and Minnesota coding of a routine ECG. Clin Exp Neurol 1987;24:21-5.
30. Gokce N, Keaney JFJ, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40.
31. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989;83:1946-52.
32. Guillen I, Blanes M, Gomez-Lechon MJ, et al. Cytokine signaling during myocardial infarction: sequential appearance of 1L-1 beta and IL-6. Am J Physiol 1995;269:R229-35.
33. Gupta S, Leatham EW, Carrington D, et al. Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
34. Gurfinkel E, Bozovich G, Daroca A, et al., for the ROXIS Study Group. Randomised trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
35. Hackett D, Davies G, Chierchia S, et al. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987;317:1055-9.
36. Hansen PR. Inflammatory alterations in the myocardial micro-circulation. J Mol Cell Cardiol 1998;30:2555-9.
37. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
38. Haynes WG, VVebb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-4.
39. Heitzer T, Just H, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
40. Heitzer T, Yla HS, Wild E, et al. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 1999;33:499-505.
41. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-20.
42. Ihling C. Pathomorphology of coronary atherosclerosis. Herz 1998;23:69-77.
43. Johnstone M, Creager S, Scales K, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-6.
44. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96-102.
45. Lefroy DC, Crake T, Uren NG, et al. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans [see comments]. Circulation 1993;88:43-54.
46. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13.
47. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44:1799-808.
48. Liao JK, Bettmann MA, Sandor T, et al. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991;68:1027-34.
49. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
50. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients < 40 years of age with coronary artery disease. Am J Cardiol 1996;78:1210-4.
51. Liuzzo G, Biasucci L, Gallimore J, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
52. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
53. Lüscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Eur Heart J 1995;16:Suppl C:51-8.
54. Matsuda Y, Ogawa H, Moritani K, et al. Coronary angiography during exercise-induced angina with ECG changes. Am Heart J 1984;108:959-66.
55. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999;99:1560-6.
56. McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-54.
57. Meredith IT, Anderson TJ, Uehata A, et al. Role of endothelium in ischemic coronary syndromes. Am J Cardiol 1993;72:27C-31C.
58. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993;87:V-56-66.
59. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126:1299-304.
60. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.
61. Münzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-94.
62. Myers PR, Parker JL, Tanner MA, et al. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bio-activity and nitric oxide production in vascular endothelium. Shock 1994;1:73-8.
63. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-8.
64. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factor for myocardial infarction. Eur Heart J 1993;14:12-6.
65. Noll G. Pathogenesis of atherosclerosis: a possible relation to infection. Atherosclerosis 1998;140 SuppI 1:S3-9.
66. Noll G, Luscher TF. The endothelium in acute coronary syndromes. Eur Heart J 1998;19:Suppl C:C30-8.
67. Noon JP, Walker BR, Hand MF, et al. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res 1998;38:480-4.
68. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes Mellitus. J Clin Invest 1997;100:678-84.
69. Okumura K, Yasue H, Matsuyama K, et al. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992;19:752-8.
70. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
71. Pohl U, Holtz J, Busse R, et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8:37-44.
72. Qiu S, Theroux P, Marcil M, et al. Plasma endothelin-1 levels in stable and unstable angina. Cardiology 1993;82:12-9.
73. Rosenberger G, Fichtlscherer S. Analysis of forearm circulation-a substitute for diagnosis of coronary atherosclerosis? Herz 1998;23:130-4.
74. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
75. Schächinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo. Importance of baseline vasomotor tone in atherosclerosis. Circulation 1995;92:2087-94.
76. Siegfried M, Ma X, Lefer A. Splanchnic vascular endothelial dysfunction in rat endotoxemia: role of superoxide radicals. Eur J Pharmacol 1992;212:171-6.
77. Sinisalo J, Mattila K, Nieminen MS, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998;41:85-92.
78. Sinisalo J, Syrjala M, Mattila KJ, et al. Endothelial release of tissue-type plasminogen activator and ischemia-induced vasodilatation are linked in patients with coronary heart disease. Blood Coagul Fibrinolys 1999;10:181-7.
79. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
80. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
81. Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-7.
82. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349:1391-2.
83. Valtonen V, Kuikka A, Syrjanen J. Thrombo-embolic complications in bacteraemic infections. Eur Heart J 1993;14:Suppl K:20-3.
84. Vane J, Anggard E, Botting R. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
85. Vanhoutte PM. The endothelium-modulator of vascular smooth-muscle tone. N Engl J Med 1988;319:512-3.
86. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6.
87. Wang P, Ba W, Chaudry I. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994;266:H2535-41.
88. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998;98:2235-40.
89. Wieczorek I, Haynes WG, Webb DJ, et al. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994;72:436-41.
90. Wilson RF, Laxson DD, Lesser JR, et al. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989;1:807-11.
91. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
92. Yang ZH, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990;82:188-95.
93. Yoshizumi M, Perella M, Burnett J Jr, et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205-9.
94. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
95. Zeiher AM. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischemia or epiphenomen? Lancet 1996;348:s10-2.
96. Zeiher AM, Drexler H, Wollschläger H, et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
97. Zeiher AM, Drexler H, Wollschläger H, et al. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
98. Zeiher AM, Goebel H, Schächinger V, et al. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995;91:941-7.
99. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094-100.
100. Zeiher AM, Schächinger V, Weitzel SH, et al. Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. Circulation 1991;83:1519-25.